Chemotherapy Induced Anemia - Market Insight, Epidemiology And Market Forecast - 2032

DelveInsight’s "Chemotherapy-induced anemia – Market Insights, Epidemiology, and Market Forecast – 2032" report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of chemotherapy-induced anemia in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Chemotherapy-induced anemia market report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Chemotherapy-induced anemia market size from 2019 to 2032, segmented by seven major markets. The report also covers the current Chemotherapy-induced anemia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying market potential.

Geographies Covered
The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Study Period: 2019–2032

Chemotherapy-induced anemia: Disease Understanding and Treatment Algorithm

Chemotherapy-induced anemia Overview

Anemia is a frequent but insidious complication of cancer and its cytotoxic chemotherapy. According to the World Health Organization (WHO) definition, anemia occurs when hemoglobin (Hb) levels drop below 12 g/dL for women and 13 g/dL for men, and severity ranges from mild to severe or life-threatening. Anemia contributes to debilitating fatigue, lethargy, cardiovascular problems, shortness of breath, and reduced cognitive function in individuals who often already have significant morbidity and diminished quality of life (QOL) due to their malignancy.

When anemia occurs as an adverse event consequent to the toxic effect of anticancer treatment, it is called chemotherapy-induced anemia (CIA). The etiology of CIA is multifactorial; the primary causes are underlying cancer and the effects of chemotherapy. Anemia resulting from underlying cancer—known as the anemia of inflammation—causes cytokine release in the patient, leading to decreased erythropoietin production by the kidney, as well as restricted availability of iron. This process results in the condition known as functional iron deficiency. Anemia due to chemotherapy is often caused by myelosuppression. In addition, certain chemotherapeutic agents, especially platinum, can result in renal dysfunction, which can further decrease erythropoietin production. Chemotherapy regimens that contain cisplatin, used to treat lung and ovarian cancer, can be associated with significant anemia in 30% or more of treated patients. Chemotherapy agents such as docetaxel are also strongly associated with chemotherapy-induced anemia. Chemotherapy agents that are less myelosuppressive and less nephrotoxic are less likely to be associated with anemia.

Although CIA is one of the most common side effects of chemotherapy, it is often not recognized and is frequently undertreated. It can adversely affect long-term patient outcomes, as the anemic environment may limit the effectiveness of some chemotherapy agents. The incidence and severity of CIA depend on various factors, including the type, schedule, and intensity of therapy administered, or whether the patient has received prior myelosuppressive chemotherapy, radiation therapy, or both. An estimated 30–90% of cancer patients receiving chemotherapy develop anemia.

Correction of anemia can be achieved by either treating the underlying etiology or by providing supportive care that may entail transfusion with packed red blood cells (PRBCs) or administration of erythropoiesis-stimulating agents (ESAs), with or without iron supplementation. The first ESA approved by the US Food and Drug Administration (FDA) for treating anemia in patients receiving myelosuppressive chemotherapy was epoetin alfa, recombinant human erythropoietin (rhEpo). A second-generation rhEpo, darbepoetin alfa, has also been FDA-approved for this indication.

ESA’s use has been a constant topic of debate. Despite the clinical benefit of ESAs for CIA, both randomized clinical studies and systematic reviews demonstrated a significantly higher risk of thromboembolic events in patients receiving ESAs for CIA.

Efforts should be made to identify the etiology of anemia, and treatment should be directed to the underlying cause. However, identifying a specific causative factor can occasionally be difficult, and directed therapeutic intervention may not be effective.

Chemotherapy-induced anemia Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnoses available in the Chemotherapy-induced anemia market to treat the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

The DelveInsight Chemotherapy-induced anemia Market Report gives a thorough understanding of chemotherapy-induced anemia by including details of disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides the treatment algorithms and treatment guidelines for Chemotherapy-induced anemia in the US, Europe, and Japan.

Chemotherapy-induced anemia Epidemiology

The Chemotherapy-induced anemia epidemiology division provides insights into the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed incident patient pool, trends, and assumptions.

Key Findings

The disease epidemiology covered in the report provides historical and forecasted Chemotherapy-induced anemia epidemiology segmented as the Incidence of chemotherapy-induced anemia, severity-specific cases of chemotherapy-induced anemia, and Incidence of chemotherapy-induced anemia per chemo cycles. The report includes the incident scenario of Chemotherapy-induced anemia symptoms in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Country-wise Chemotherapy-induced anemia Epidemiology

The epidemiology segment also provides the Chemotherapy-induced anemia epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The incident Chemotherapy-induced anemia population in the 7MM countries was estimated to be ~1.6 million cases in 2021.

Chemotherapy-induced anemia Drug Chapters

The drug chapter segment of the Chemotherapy-induced anemia report encloses the detailed analysis of Chemotherapy-induced anemia marketed drugs and late stage (Phase-III, Phase-II/III, Phase-II, and Phase-I/II) pipeline drugs. It also helps to understand the Chemotherapy-induced anemia clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Correction of anemia can be achieved by either treating the underlying etiology or by providing supportive care that may entail transfusion with packed red blood cells (PRBCs) or administration of erythropoiesis-stimulating agents (ESAs), with or without iron supplementation. The decision regarding the best treatment is dependent on many factors. While PRBC transfusion is the only option if the patient requires an immediate boost in Hb levels, consideration of ESA therapy and iron supplementation may be warranted for the long-term management of anemia as determined by risk assessment.

Products detail in the report…

Chemotherapy-induced anemia Emerging Drugs

Roxadustat (FG-4592), an oral medication, is the first in a new class of medicines comprising hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin, improved iron absorption and mobilization, and downregulation of hepcidin. Roxadustat has been approved in European Union (EU) member states, including the European Economic Area (EEA) countries, as well as in Japan, China, Chile, and South Korea for the treatment of anemia of CKD in adult patients on dialysis (DD) and not on dialysis (NDD).

The drug has completed its evaluation in Phase II in patients with CIA. Roxadustat is also in clinical development for anemia of chronic kidney disease (CKD) and anemia associated with myelodysplastic syndromes (MDS).

Products detail in the report…

Chemotherapy-induced anemia Market Outlook

The Chemotherapy-induced anemia market outlook of the report builds a detailed comprehension of the historical, current, and forecasted Chemotherapy-induced anemia market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of the Chemotherapy-induced anemia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Chemotherapy-induced anemia market in the 7MM is expected to change in the study period 2019–2032.

Currently, different short- and long-acting formulations of ESAs are available. The first ESA was approved by the US FDA for the treatment of anemia in patients receiving myelosuppressive chemotherapy as epoetin alfa (Epogen/ Procrit), recombinant human erythropoietin (rhEpo). A second-generation rhEpo, darbepoetin alfa (Aranesp), has also been FDA-approved for this indication. After their approval for the CIA, their use expanded tremendously (Bloudek & Carlson, 2021).

Several biosimilar epoetin options have become accessible since the patent expiration of epoetin alfa. The FDA recently approved the biosimilar for treating anemia, epoetin alfa-epbx (Retacrit). It was launched at a 33.5% discount to reference Epogen.

Key Findings

This section includes a glimpse of the Chemotherapy-induced anemia market in the 7MM. The market size of chemotherapy-induced anemia in the seven major markets was over USD 1 billion in 2021.

The United States: Market Outlook

This section provides the total Chemotherapy-induced anemia market size and market size by therapies of Chemotherapy-induced anemia in the United States.

The United States accounts for the highest market size of chemotherapy-induced anemia compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

In order to cater to the current unmet needs in the CIA treatment, Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors have emerged as a new class of orally-administered agents for the management of anemia in chemotherapy. They induce considerably lower but more consistent erythropoietin levels than ESAs, and it has been hypothesized that they could cause fewer adverse cardiovascular events than ESAs.

The pipeline for CIA is currently limited, consisting of only one key asset, i.e., roxadustat, the HIF-PH inhibitor, which has completed its investigation in Phase II in 2021. Other assets in development include ALRN-6924 and Desidustat.

To conclude, with growing cancer cases, the incidence of CIA is likely to increase in the coming years, escalating the need for treatment. Thus, more clinical studies to bring novel treatment are needed to address the unmet needs in the treatment of anemia in cancer patients receiving chemotherapy.

EU-5 Countries: Market Outlook

The total Chemotherapy-induced anemia market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are also mentioned.

Japan Market Outlook

The total Chemotherapy-induced anemia market size and market size by therapies of Chemotherapy-induced anemia in Japan are also mentioned.

Chemotherapy-induced anemia Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2019–2032. The analysis covers Chemotherapy-induced anemia market uptake by drugs, patient uptake by therapies, and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Chemotherapy-induced anemia Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II/III, Phase II, and Phase I/II stage. It also analyses chemotherapy-induced anemia’s key players involved in developing targeted therapeutics.

Major players include Astellas/FibroGen/AstraZeneca, Aileron Therapeutics and Zydus Cadila, and others, whose key products are expected to get launched in the US market by 20XX.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, and patent details for Chemotherapy-induced anemia emerging therapies.

KOL Views

To keep up with current market trends, we take KOLs and SMEs’ opinions working in the Chemotherapy-induced anemia domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Chemotherapy-induced anemia market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform a Competitive and Market Intelligence analysis of the Chemotherapy-induced anemia market using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report
The report covers the descriptive overview of chemotherapy-induced anemia, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
Comprehensive insight is provided into the Chemotherapy-induced anemia epidemiology and treatment in the 7MM
Additionally, an all-inclusive account of both the current and emerging therapies for chemotherapy-induced anemia is provided, along with the assessment of new therapies, which will impact the current treatment landscape.
A detailed review of the Chemotherapy-induced anemia market; historical and forecasted, is included in the report, covering drug outreach in the 7MM
The report provides an edge while developing business strategies by understanding trends shaping and driving the global Chemotherapy-induced anemia market

Report Highlights
In the coming years, the Chemotherapy-induced anemia market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
The companies and academics are working to assess challenges and seek opportunities that could influence Chemotherapy-induced anemia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
Major players are involved in developing therapies for chemotherapy-induced anemia. The launch of emerging therapies will significantly impact the Chemotherapy-induced anemia market.
A better understanding of disease pathogenesis will also contribute to developing novel therapeutics for chemotherapy-induced anemia.
Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competitor, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Chemotherapy-induced anemia Report Insights
Patient Population
Therapeutic Approaches
Chemotherapy-induced anemia Pipeline Analysis
Chemotherapy-induced anemia Market Size and Trends
Market Opportunities
Impact of upcoming Therapies

Chemotherapy-induced anemia Report Key Strengths
11-year Forecast
7MM Coverage
Chemotherapy-induced anemia Epidemiology Segmentation
Key Competitors
Highly Analyzed Market
Drugs Uptake

Chemotherapy-induced anemia Report Assessment
Current Treatment Practices
Unmet Needs
Pipeline Product Profiles
Market Attractiveness
Market Drivers and Barriers

Key Questions

Market Insights:
What was the market share (%) distribution, and how would it look in 2032?
What would be the Chemotherapy-induced anemia total market size and market size by therapies across the 7MM during the forecast period (2019–2032)?
What are the key findings pertaining to the market across 7MM, and which country will have the largest Chemotherapy-induced anemia market Size during the forecast period (2019–2032)?
At what CAGR is the Chemotherapy-induced anemia market expected to grow in the 7MM during the forecast period (2019–2032)?
What would be the Chemotherapy-induced anemia market outlook across the 7MM during the forecast period (2019–2032)?
What would be the Chemotherapy-induced anemia market growth till 2032 and the resultant market Size in the year 2032?
How would the future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:
What are the disease risk, burden, and unmet needs of chemotherapy-induced anemia?
What is the historical patient pool of chemotherapy-induced anemia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What would be the forecasted patient pool of chemotherapy-induced anemia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What will be the growth opportunities in the 7MM concerning the patient population pertaining to chemotherapy-induced anemia?
Out of all 7MM countries, which country would have the highest incidence of chemotherapy-induced anemia during the forecast period (2019–2032)?
At what CAGR is the population expected to grow in the 7MM during the forecast period (2019–2032)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
What are the current options for the treatment of chemotherapy-induced anemia?
What are the current treatment guidelines for treating chemotherapy-induced anemia in the USA, Europe, and Japan?
What are the chemotherapy-induced anemia marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
How many companies are developing therapies for the treatment of chemotherapy-induced anemia?
How many therapies are developed by each company for the treatment of chemotherapy-induced anemia?
How many emerging therapies are in the mid-stage and late stages of development to treat chemotherapy-induced anemia?
What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chemotherapy-induced anemia therapies?
What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for chemotherapy-induced anemia and its status?
Which key designations have been granted for the emerging therapies for chemotherapy-induced anemia?
What are the global historical and forecasted markets for chemotherapy-induced anemia?

Reasons to buy
The report will help in developing business strategies by understanding trends shaping and driving the Chemotherapy-induced anemia market
To understand the future market competition in the Chemotherapy-induced anemia market and an Insightful review of the key market drivers and barriers.
Organize sales and marketing efforts by identifying the best opportunities for Chemotherapy-induced anemia in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Identifying strong upcoming players in the market will help devise strategies that will help get ahead of competitors.
Organize sales and marketing efforts by identifying the best opportunities for the Chemotherapy-induced anemia market.
To understand the future market competition in the Chemotherapy-induced anemia market.